All In MedTech

Device Trial Radar · NCT00631540

REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent

Last checked: Nov 20, 2026Latest source record: Dec 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

Feb 2008

Primary completion

May 2010

Study completion May 2012

Sponsor

Lead sponsor
Cook Group IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Mar 7, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and effectiveness of the Formula Balloon-Expandable Stent in treatment of renal artery stenosis.

Conditions

  • Renal Artery Stenosis

Interventions

  • Formula Balloon-Expandable StentDevice

    renal artery stenting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Patency of the Treated Renal ArteryTime frame: 9 Months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Munroe Regional Medical Center

    Ocala, Florida

  • Orlando Regional Medical Center

    Orlando, Florida

  • Lenox Hill Hospital

    New York, New York

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.